Apollomics Inc. Class A Ordinary Shares Total Assets
Apollomics Inc. Class A Ordinary Shares total assets. Based on the latest financial reports, Apollomics Inc. Class A Ordinary Shares (APLM) holds total assets worth $6.71 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see market cap of Apollomics Inc. Class A Ordinary Shares for the company's overall valuation and market capitalisation.
Total Assets of Apollomics Inc. Class A Ordinary Shares (2019–2025)
Total assets of Apollomics Inc. Class A Ordinary Shares from 2019 to 2025. This chart illustrates how Apollomics Inc. Class A Ordinary Shares's total assets have evolved over time, based on quarterly financial data. See current stock price of Apollomics Inc. Class A Ordinary Shares for real-time trading data and today's change.
Apollomics Inc. Class A Ordinary Shares - Asset Composition Analysis
Apollomics Inc. Class A Ordinary Shares Total Assets Breakdown (December 2025)
Apollomics Inc. Class A Ordinary Shares total assets breakdown as of December 2025. Apollomics Inc. Class A Ordinary Shares's total assets of $6.71 Million consist of 90.1% current assets and 9.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 48.8% |
| Accounts Receivable | $2.49 Million | 37.1% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how Apollomics Inc. Class A Ordinary Shares's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Apollomics Inc. Class A Ordinary Shares (APLM) working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Apollomics Inc. Class A Ordinary Shares's current assets represent 90.1% of total assets in 2025, a decrease from 95.4% in 2019.
- Cash Position: Cash and equivalents constituted 48.8% of total assets in 2025, up from 48.7% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 1.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 37.1% of total assets.
Apollomics Inc. Class A Ordinary Shares Competitors by Total Assets
Key competitors of Apollomics Inc. Class A Ordinary Shares based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Apollomics Inc. Class A Ordinary Shares - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.96 | 1.39 | 0.48 |
| Quick Ratio | 0.96 | 1.39 | 0.48 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-275.00K | $2.87 Million | $-59.49K |
Apollomics Inc. Class A Ordinary Shares - Advanced Valuation Insights
This section examines the relationship between Apollomics Inc. Class A Ordinary Shares's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 8.15 |
| Latest Market Cap to Assets Ratio | 4.48 |
| Asset Growth Rate (YoY) | -48.7% |
| Total Assets | $6.71 Million |
| Market Capitalization | $30.09 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Apollomics Inc. Class A Ordinary Shares's assets at a significant premium (4.48x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Apollomics Inc. Class A Ordinary Shares's assets decreased by 48.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Apollomics Inc. Class A Ordinary Shares (2019–2025)
The table below shows the annual total assets of Apollomics Inc. Class A Ordinary Shares from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $6.71 Million | -48.74% |
| 2024-12-31 | $13.10 Million | -76.35% |
| 2023-12-31 | $55.39 Million | -27.58% |
| 2022-12-31 | $76.47 Million | -38.05% |
| 2021-12-31 | $123.44 Million | -27.36% |
| 2020-12-31 | $169.94 Million | +114.97% |
| 2019-12-31 | $79.05 Million | -- |
About Apollomics Inc. Class A Ordinary Shares
Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung… Read more